Russia's RDIF signs deal to produce Sputnik V vaccine in China

Reuters, 29.03.2021

MOSCOW (Reuters) - Russia’s RDIF sovereign wealth fund and China’s Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia’s Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.

RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.